RVMD Revolution Medicines Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RVMD

Price (delayed)

$40.2

Market cap

$6.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.86

Enterprise value

$6.01B

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities ...

Highlights
The company's equity has surged by 167% YoY and by 118% QoQ
RVMD's quick ratio is up by 35% since the previous quarter and by 23% year-on-year
Revolution Medicines's net income has plunged by 75% YoY and by 32% from the previous quarter
The revenue has dropped by 67% year-on-year and by 56% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://revolutionmedicines.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RVMD
Market
Shares outstanding
164.69M
Market cap
$6.62B
Enterprise value
$6.01B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.41
Price to sales (P/S)
392.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
518.94
Earnings
Revenue
$11.58M
EBIT
-$439.59M
EBITDA
-$430.28M
Free cash flow
-$358.3M
Per share
EPS
-$3.86
Free cash flow per share
-$3.17
Book value per share
$16.67
Revenue per share
$0.1
TBVPS
$17.58
Balance sheet
Total assets
$2.06B
Total liabilities
$235.51M
Debt
$87.94M
Equity
$1.83B
Working capital
$1.74B
Liquidity
Debt to equity
0.05
Current ratio
13.06
Quick ratio
12.91
Net debt/EBITDA
1.42
Margins
EBITDA margin
-3,715.7%
Gross margin
100%
Net margin
-3,768.3%
Operating margin
-4,207.1%
Efficiency
Return on assets
-33.6%
Return on equity
-38.4%
Return on invested capital
-59.7%
Return on capital employed
-22.9%
Return on sales
-3,796.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RVMD stock price

How has the Revolution Medicines stock price performed over time
Intraday
2.58%
1 week
11.79%
1 month
28.07%
1 year
68.69%
YTD
40.17%
QTD
24.73%

Financial performance

How have Revolution Medicines's revenue and profit performed over time
Revenue
$11.58M
Gross profit
$11.58M
Operating income
-$487.19M
Net income
-$436.37M
Gross margin
100%
Net margin
-3,768.3%
The net margin has plunged by 198% from the previous quarter
Revolution Medicines's operating margin has plunged by 198% from the previous quarter
RVMD's operating income has dropped by 89% year-on-year and by 32% since the previous quarter
Revolution Medicines's net income has plunged by 75% YoY and by 32% from the previous quarter

Growth

What is Revolution Medicines's growth rate over time

Valuation

What is Revolution Medicines stock price valuation
P/E
N/A
P/B
2.41
P/S
392.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
518.94
The EPS has declined by 25% year-on-year and by 19% since the previous quarter
The company's equity has surged by 167% YoY and by 118% QoQ
The P/B is 31% lower than the 5-year quarterly average of 3.5 and 7% lower than the last 4 quarters average of 2.6
The stock's price to sales (P/S) is 185% more than its last 4 quarters average of 137.9
The revenue has dropped by 67% year-on-year and by 56% since the previous quarter

Efficiency

How efficient is Revolution Medicines business performance
The return on sales has dropped by 196% since the previous quarter
RVMD's ROIC is down by 26% year-on-year
Revolution Medicines's return on equity has increased by 7% YoY

Dividends

What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVMD.

Financial health

How did Revolution Medicines financials performed over time
RVMD's total assets has soared by 154% year-on-year and by 109% since the previous quarter
Revolution Medicines's total liabilities has soared by 86% YoY and by 60% from the previous quarter
The debt is 95% less than the equity
The company's equity has surged by 167% YoY and by 118% QoQ
The debt to equity has contracted by 44% YoY and by 38% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.